INTRODUCTION AND OBJECTIVES:
The mammalian target of rapamycin (mTOR) pathway is known to play an important role in oncology. However, its role in prostate cancer (PCa) has not been fully understood. The aim of the study was to evaluate the expression of mTOR, phosphorylated-mTOR (p-mTOR) and Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) in patients with PCa using tissue microarray (TMA) technique and to assess their correlation with clinico-pathological parameters and outcome.
METHODS: Tissue samples from 115 consecutive patients who underwent radical prostatectomy were constructed to a TMA. In every case four localisations were included: A) from the tumour center, B) malignant border of the tumour, C) tumour adjacent benign tissue and D) tumour-distant benign prostatic tissue. Expression scores were strati ed according to their respective median immune reactive score 0-12 into 'weak' (< median) and 'strong' (¼ median). A meta-analysis of studies from Medline, Scopus and Web of knowledge were retrieved to investigate the association between biochemical recurrence and mTOR pathways immunostaining.
RESULTS: Expression scores of mTOR, in A, B, C and D were 9. 1, 8.8, 5.0 and 6.8 (p<0.01) , p-mTOR scores were 7.4, 7.2, 2.0, 4.6 (p<0.01) while 4E-BP1 scores were 8.0, 7.6, 2.6 and 3.1 (p<0.01), respectively. We observed lower p-mTOR scores in A samples (6.3 and 7.9; p¼0.01) in locally advanced vs. organ con ned PCa. Overall, 523 studies were identi ed from the databases and relevant references and 4 studies were added to our cohort for the meta-analysis. We found that 'strong' staining of p-mTOR was associated with lower risk of BCR (biochemical recurrence) (risk ratio [RR]¼ 0.57; p¼0.002) while no association for mTOR (RR¼ 0.70; p¼0.13) or 4E-BP1 (RR¼ 0.86; p¼0.53) was found (Figure 1) . CONCLUSIONS: All 3 markers showed local gradients of expression in PCa tissue. Moreover, expression characteristics suggest disorders in the mTOR system. In particular p-mTOR was associated with more aggressive PCa and could be clinically useful as a prognostic marker for BCR and to assess their local diversity as well as their correlation with clinico-pathological parameters.
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MP29-04 COMBINATION THERAPY WITH EPI-002 AND IONIZING RADIATION FOR CASTRATION-RESISTANT PROSTATE CANCER
Yusuke Ito*, C. Adriana Banuelos, Marianne D. Sadar, Vancouver, Canada INTRODUCTION AND OBJECTIVES: Targeted radiotherapy with radium 223 dichloride for metastatic castration resistant prostate cancer (mCRPC) increases overall survival (OS) of patients with bone metastases by approximately 3 months. Emerging evidence supports that androgen receptor (AR) signaling regulates DNA repair in prostate cancer. Thus a combination approach using AR modulating drugs with radiation could be a promising option for the treatment of mCRPC. All currently approved AR modulating drugs, such as enzalutamide and abiraterone, either directly or indirectly target the AR C-terminus ligandbinding domain (LBD). Such drugs are often unsuccessful due to the emergence of AR splice variants (ARV-7, ARv567es) that are constitutively active and lack a LBD. EPI-002 is a first-in-class AR antagonist that binds to its N-terminus domain to target both full-length AR and AR splice variants such as AR-V7. Here we present data to support that a combination of EPI-002 and ionizing radiation has beneficial effects in vitro.
METHODS: Combination therapy using EPI-002 and ionizing radiation were evaluated in vitro using LNCaP95 human prostate cancer cells. This cell line is androgen-independent, expresses full-length AR and AR-V7, and is resistant to enzalutamide and other antiandrogens. Proliferation was evaluated using BrdU incorporation and colony formation assays. The effects of monotherapy and combination therapy on cell cycle and DNA damage were analysed using FACS and Western blot.
RESULTS: Ionizing radiation increased the expression of fulllength AR and AR splice variants and their gene targets, PSA and TMPRSS2. EPI-002 induced G1 cell cycle arrest whereas radiation induced G2/M cell cycle arrest. FACS analysis showed dose-dependent blocking of BrdU incorporation and more accumulation of gammaH2AX in S phase cells in the combination therapy at higher doses of ionizing radiation compared to monotherapy. Combination therapy suggests a synergistic inhibitory effect on proliferation of LNCaP95 cells.
CONCLUSIONS: Consistent with previous reports, radiation increased expression of full-length AR expression. Building on these data, here we show for the first time that radiation also increases the expression of AR splice variants thereby implying a possible METHODS: AR CNV analysis by digital PCR was tested using genomic DNA (gDNA) from VCaP cell line and cfDNA from mouse xenografted with VCaP. AR mutation analysis by deep sequencing and digital PCR was tested using gDNA from LNCaP cell line and cfDNA from mouse xenografted with LNCaP. Next, we evaluated AR status in cfDNA from 92 CRPC patients. The association between AR status and clinicopathological factors was evaluated.
RESULTS: AR amplification was detectable in VCaP gDNA to 1.0% dilution, and also in VCaP xenograft cfDNA. AR mutation was detectable in LNCaP gDNA to 0.1% dilution by digital PCR, and to 1.0% dilution by deep sequencing. AR mutation was also detectable in LNCaP xenograft cfDNA. Of the 92 CRPC patients, AR amplification and mutation were detected in 45 (48.9%) and 19 (20.65%), respectively. Most of the mutations were in known hotspots on the ligand binding domain. Nine patients with AR mutation had multiple mutations. Overall, 54 (58.7%) of 92 patients had AR aberrations (amplification and/or mutation), and 10 had both AR amplification and mutation. In univariate analysis, clinicopathological factors associated with the presence of AR aberrations in cfDNA included higher PSA, higher cfDNA concentration and resistance to estramustine, enzalutamide, or abiraterone.
CONCLUSIONS: AR status in cfDNA could be analyzed by digital PCR and deep sequencing with high fidelity, and the rates of AR aberrations in our data was comparable to that in other reports. AR aberrarions in cfDNA might be a potential biomarker in CRPC.
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MP29-06 INCREASED PRO-TUMORIGENIC PROPERTIES OF PROSTATE FIBROBLASTS IN AFRICAN AMERICAN MEN COMPARED TO CAUCASIANS
Marc Gillard, Chicago, IL; Susan Crawford, Charles Brendler, Evanston, IL; Donald Vander Griend, Chicago, IL; Omar Franco*, Evanston, IL INTRODUCTION AND OBJECTIVES: Despite advances in the diagnosis and treatment of prostate cancer (PCa), the incidence and death rate is still significantly higher for African Americans (AA) compared to Caucasian (CAU) men. cDNA microarray studies revealed that immune-inflammatory response, apoptosis and focal adhesion were differentially increased in AA vs. CAU prostate tumors. We have shown that chronic activation of pro-inflammatory cytokines and chemokines in prostate CAF increase tumor progression. However the biological effects of fibroblasts in the TME of AA patients has not been intensively studied due to the lack of suitable models. Here we isolated fibroblasts from human prostate tissues from AA patients with PCa and compared the biological effects on several PCa cell lines to evaluate the similarities and/or differences to those from CAU-derived fibroblasts METHODS: Prostate fibroblasts were isolated from patients AA (PrF-AA) and CAU (PrF-CAU) undergoing robotic assisted laparoscopic
